Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 5/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29960836 | 0.83 | TAAR1 (0.52) | TAAR1HTR2ATRPM8MAOBHTR2C | |
| SCHEMBL16268636 | 0.83 | TAAR1 (0.52) | TAAR1HTR2ATRPM8MAOBHTR2C | |
| SCHEMBL965997 | 0.83 | PYCR1 (0.46) | TAAR1PYCR1IDO1HTTCYP1A2 | |
| Hydrochloric Acid SCHEMBL18524119 | 0.82 | TAAR1 (0.50) | TAAR1HTR2ATRPM8MAOBHTR2C | |
| Hydrochloric Acid SCHEMBL31033443 | 0.81 | PYCR1 (0.45) | TAAR1PYCR1IDO1HTTCYP1A2 | |
| SCHEMBL10830804 | 0.81 | PYCR1 (0.45) | PYCR1IDO1HTTCYP1A2CYP3A4 | |
| SCHEMBL3634811 | 0.79 | PYCR1 (0.44) | PYCR1IDO1HTTCYP1A2CYP3A4 | |
| SCHEMBL811131 | 0.79 | PYCR1 (0.47) | PYCR1IDO1HTTCYP1A2CYP3A4 | |
| SCHEMBL473578 | 0.78 | IDO1 (0.56) | TAAR1HTR2ATRPM8MAOBIDO1 | |
| SCHEMBL29787088 | 0.78 | IDO1 (0.56) | TAAR1HTR2ATRPM8MAOBIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-4303216-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2022184152-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-09-09 | — | — | WO | disclosed |
| CN-113166139-A | Pyrrolo [2,3-b ] pyridines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10138236-B2 | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-27 | — | — | US | disclosed |
| EP-3197891-B1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | Bayer Pharma AG (DE) | 2018-11-21 | — | — | EP | disclosed |
| EP-3144303-B1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20170275282-A1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2011-05-05 | — | — | US | disclosed |
| EP-2307397-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7868003-B2 | Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| EP-2155734-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009158426-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158426-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2008144223-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138236-B2 | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | F13B, TFPI, TFPI2 | TAAR1 4130/4885HTR2A 616/4885TRPM8 2682/4885 |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | GPR52, CD22, CD4 | TAAR1 337/4885HTR2A 258/4885TRPM8 2655/4885 |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | REN, MTNR1B, MTNR1A | TAAR1 601/4885HTR2A 379/4885TRPM8 3487/4885 |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, HASPIN | TAAR1 4761/4885HTR2A 3878/4885TRPM8 2833/4885 |
| US-20170275282-A1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | F13B, TFPI, TFPI2 | TAAR1 4130/4885HTR2A 616/4885TRPM8 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.